Pelthos Therapeutics Inc. (PTHS)

• Market cap: $17.1M
• 1 day: -30.82%
• 5 days: 2.92%
• 1 month: 35.70%
• 3 months: 40.92%
• 6 months: 103.56%
• Year to date: 153.39%
• 1 year: 45.40%
• 5 years: -61.83%
• 10 years: -61.83%
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: Pelthos Therapeutics Inc is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic, visceral pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.

Employees: 11

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

5,178% more capital invested

Capital invested by funds: $16K [Q4 2024] → $846K (+$830K) [Q1 2025]

500% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 1

125% more funds holding

Funds holding: 4 [Q4 2024] → 9 (+5) [Q1 2025]

9.35% more ownership

Funds ownership: 0.41% [Q4 2024] → 9.77% (+9.35%) [Q1 2025]